JPWO2021092134A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021092134A5 JPWO2021092134A5 JP2022526118A JP2022526118A JPWO2021092134A5 JP WO2021092134 A5 JPWO2021092134 A5 JP WO2021092134A5 JP 2022526118 A JP2022526118 A JP 2022526118A JP 2022526118 A JP2022526118 A JP 2022526118A JP WO2021092134 A5 JPWO2021092134 A5 JP WO2021092134A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- dll3
- agent
- day
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025113736A JP2025148407A (ja) | 2019-11-10 | 2025-07-04 | 抗ｄｌｌ３剤の投与レジメン |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19208214.7A EP3819312A1 (en) | 2019-11-10 | 2019-11-10 | Dosing regimen for anti-dll3 agents |
| EP19208214.7 | 2019-11-10 | ||
| US202063078131P | 2020-09-14 | 2020-09-14 | |
| US63/078,131 | 2020-09-14 | ||
| PCT/US2020/059052 WO2021092134A1 (en) | 2019-11-10 | 2020-11-05 | Dosing regimen for anti-dll3 agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113736A Division JP2025148407A (ja) | 2019-11-10 | 2025-07-04 | 抗ｄｌｌ３剤の投与レジメン |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023501375A JP2023501375A (ja) | 2023-01-18 |
| JP2023501375A5 JP2023501375A5 (https=) | 2023-11-13 |
| JPWO2021092134A5 true JPWO2021092134A5 (https=) | 2023-11-13 |
| JP7709434B2 JP7709434B2 (ja) | 2025-07-16 |
Family
ID=68531385
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526118A Active JP7709434B2 (ja) | 2019-11-10 | 2020-11-05 | 抗ｄｌｌ３剤の投与レジメン |
| JP2025113736A Pending JP2025148407A (ja) | 2019-11-10 | 2025-07-04 | 抗ｄｌｌ３剤の投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113736A Pending JP2025148407A (ja) | 2019-11-10 | 2025-07-04 | 抗ｄｌｌ３剤の投与レジメン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230174643A1 (https=) |
| EP (2) | EP3819312A1 (https=) |
| JP (2) | JP7709434B2 (https=) |
| KR (1) | KR20220097470A (https=) |
| CN (2) | CN120053637A (https=) |
| AR (1) | AR120399A1 (https=) |
| AU (1) | AU2020377981A1 (https=) |
| CA (1) | CA3156229A1 (https=) |
| IL (1) | IL292463A (https=) |
| JO (1) | JOP20220104A1 (https=) |
| MX (1) | MX2022005596A (https=) |
| TN (1) | TN2022000113A1 (https=) |
| TW (1) | TWI908743B (https=) |
| UY (1) | UY38948A (https=) |
| WO (1) | WO2021092134A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025508786A (ja) * | 2022-02-23 | 2025-04-10 | アムジェン インコーポレイテッド | Ｄｌｌ３を標的とする癌治療 |
| TW202509075A (zh) * | 2023-05-19 | 2025-03-01 | 德商百靈佳殷格翰國際股份有限公司 | T細胞銜接蛋白治療癌症之用途 |
| TW202530259A (zh) * | 2023-09-21 | 2025-08-01 | 大陸商樂普創一生物科技（上海）有限公司 | 抗ｄｌｌ３抗體及其用途 |
| WO2025190281A1 (en) * | 2024-03-11 | 2025-09-18 | Lepu Biopharma Co., Ltd. | Anti-dll3 antibodies and uses thereof |
| TW202602488A (zh) | 2024-03-11 | 2026-01-16 | 美商安進公司 | 治療ｄｌｌ３陽性癌症受試者中腦轉移之方法 |
| WO2026060304A1 (en) | 2024-09-13 | 2026-03-19 | Amgen Inc. | Subcutaneous administration of anti-dll3 agent for treatment of cancer |
| WO2026075950A1 (en) | 2024-10-01 | 2026-04-09 | Amgen Inc. | Dosing regimen for anti-dll3 agent |
| CN120168667B (zh) * | 2025-03-18 | 2026-04-14 | 中国科学院近代物理研究所 | 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| DE602004030811D1 (de) | 2003-10-16 | 2011-02-10 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| PE20190658A1 (es) * | 2012-02-24 | 2019-05-08 | Abbvie Stemcentrx Llc | Moduladores y metodos de empleo novedosos |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| CN108136015A (zh) * | 2015-08-20 | 2018-06-08 | 艾伯维施特姆森特克斯有限责任公司 | 抗dll3抗体药物缀合物以及使用方法 |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| SG11201900616UA (en) * | 2016-08-02 | 2019-02-27 | Visterra Inc | Engineered polypeptides and uses thereof |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| MX2019013142A (es) * | 2017-05-05 | 2019-12-16 | Amgen Inc | Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion. |
-
2019
- 2019-11-10 EP EP19208214.7A patent/EP3819312A1/en active Pending
-
2020
- 2020-11-05 TN TNP/2022/000113A patent/TN2022000113A1/en unknown
- 2020-11-05 CA CA3156229A patent/CA3156229A1/en active Pending
- 2020-11-05 US US17/775,520 patent/US20230174643A1/en active Pending
- 2020-11-05 CN CN202510215960.8A patent/CN120053637A/zh active Pending
- 2020-11-05 UY UY0001038948A patent/UY38948A/es unknown
- 2020-11-05 EP EP20886079.1A patent/EP4054636A4/en active Pending
- 2020-11-05 JP JP2022526118A patent/JP7709434B2/ja active Active
- 2020-11-05 AR ARP200103072A patent/AR120399A1/es unknown
- 2020-11-05 MX MX2022005596A patent/MX2022005596A/es unknown
- 2020-11-05 AU AU2020377981A patent/AU2020377981A1/en active Pending
- 2020-11-05 IL IL292463A patent/IL292463A/en unknown
- 2020-11-05 TW TW109138598A patent/TWI908743B/zh active
- 2020-11-05 WO PCT/US2020/059052 patent/WO2021092134A1/en not_active Ceased
- 2020-11-05 CN CN202080079658.XA patent/CN114746117B/zh active Active
- 2020-11-05 KR KR1020227018942A patent/KR20220097470A/ko active Pending
-
2022
- 2022-05-09 JO JOP/2022/0104A patent/JOP20220104A1/ar unknown
-
2025
- 2025-07-04 JP JP2025113736A patent/JP2025148407A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI849895B (zh) | 雙特異性抗體 | |
| JP2022513420A5 (https=) | ||
| JP2008247926A (ja) | 低毒性のヒトインターフェロン−αアナログ | |
| JP2018506550A5 (https=) | ||
| JP2019031567A5 (https=) | ||
| HRP20231338T1 (hr) | Kombinirana terapija hbv | |
| JP2021512107A5 (https=) | ||
| JP2021514003A5 (https=) | ||
| JPWO2021092134A5 (https=) | ||
| JP2018535961A5 (https=) | ||
| JP2019532970A5 (https=) | ||
| JP2015172060A5 (https=) | ||
| TWI862565B (zh) | 雙特異性抗體 | |
| JPWO2017172771A5 (https=) | ||
| JPWO2022240688A5 (https=) | ||
| JP7669339B2 (ja) | メタロチオネイン抗体およびそれらの使用 | |
| JPWO2021123902A5 (https=) | ||
| JPWO2020128049A5 (https=) | ||
| US12594320B2 (en) | Method for treating checkpoint inhibitors induced adverse events | |
| JP2020520905A5 (https=) | ||
| JPWO2020245766A5 (https=) | ||
| JPWO2023133577A5 (https=) | ||
| JPWO2020222668A5 (https=) | ||
| RU2026104179A (ru) | Способы лечения множественной миеломы | |
| JPWO2023099622A5 (https=) |